Retraction Hepatitis c virus stabilizes hypoxia-inducible factor 1α and stimulates the synthesis of vascular endothelial growth factor (Journal of Virology (2007)81:19 (10249–10257) DOI: 10.1128/JVI.00763-07);Hepatitis C virus stabilizes hypoxia-inducible factor 1α and stimulates the synthesis of vascular endothelial growth factor

Journal of Virology

Volumn 81, Issue 19, 2007, Pages 10249-10257

  Nasimuzzaman, Md ^a   Waris, Gulam ^a,c   Mikolon, David ^b   Stupack, Dwayne G ^b   Siddiqui, Aleem ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c The Chicago Medical College   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; STAT3 PROTEIN; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CHORIOALLANTOIS; CONTROLLED STUDY; GENE EXPRESSION; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; VIRUS EXPRESSION; VIRUS GENE;

HEPATITIS C VIRUS;

ANIMALS; BIOLOGICAL ASSAY; CHICK EMBRYO; CHORIOALLANTOIC MEMBRANE; GENE EXPRESSION; HEPACIVIRUS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MAP KINASE KINASE KINASES; NEOVASCULARIZATION, PHYSIOLOGIC; NF-KAPPA B; PROMOTER REGIONS, GENETIC; STAT3 TRANSCRIPTION FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 34648830896     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01403-20     Document Type: Erratum

References (50)

1. Appel, N., T. Schaller, F. Penin, and R. Bartenschlager. 2006. From structure to function: new insights into hepatitis C virus RNA replication. J. Biol. Chem. 281:9833-9836.
2. Brooks, P. C., A. M. Montgomery, and D. A. Cheresh. 1999. Use of the 10-day-old chick embryo model for studying angiogenesis. Methods Mol. Biol. 129:257-269.
3. Buchler, P., H. A. Reber, M. Buchler, S. Shrinkante, M. W. Buchler, H. Friess, G. L. Semenza, and O. J. Hines. 2003. Hypoxia-inducible factor 1 regulates vascular endothelial growth factor expression in human pancreatic cancer. Pancreas 26:56-64.
4. Chandel, N. S., D. S. McClintock, C. E. Feliciano, T. M. Wood, J. A. Melendez, A. M. Rodriguez, and P. T. Schumacker. 2000. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1α; during hypoxia: a mechanism of O2 sensing. J. Biol. Chem. 275:25130-25138.
5. Choi, J., and J. H. Ou. 2006. Mechanisms of liver injury III. Oxidative stress in the pathogenesis of hepatitis C virus. Am. J. Physiol. Gastrointest. Liver Physiol. 290:G847-G851.
6. Dubuisson, J., F. Penin, and D. Moradpour. 2002. Interaction of hepatitis C virus proteins with host cell membranes and lipids. Trends Cell Biol. 12:51.
7. Dvorak, H. F., T. M. Sioussat, L. F. Brown, B. Berse, J. A. Nagy, A. Sotrel, E. J. Manseau, L. Van de Water, and D. R. Senger. 1991. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J. Exp. Med. 174:1275-1278.
8. Ebert, B. L., and H. F. Bunn. 1998. Regulation of transcription by hypoxia requires a multiprotein complex that includes hypoxia-inducible factor 1, an adjacent transcription factor, and p300/CREB binding protein. Mol. Cell. Biol. 18:4089-4096.
9. Figueroa, Y. G., A. K. Chan, R. Ibrahim, Y. Tang, M. E. Burow, J. Alam, A. B. Scandurro, and B. S. Beckman. 2002. NF-κB plays a key role in hypoxia-inducible factor-1-regulated erythropoietin gene expression. Exp. Hematol. 30:1419-1427.
10. Folkman, J. 1985. Tumor angiogenesis. Adv. Cancer Res. 43:175-203.
11. Gong, G., G. Waris, R. Tanveer, and A. Siddiqui. 2001. Human hepatitis C virus NS5A protein alters intracellular calcium levels, induces oxidative stress, and activates STAT-3 and NF-κB. Proc. Natl. Acad. Sci. USA 98:9599-9604.
12. Guo, J. T., V. V. Bichko, and C. Seeger. 2001. Effect of alpha interferon on the hepatitis C virus replicon. J. Virol. 75:8516-8523.
13. Hanahan, D., and J. Folkman. 1996. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364.
14. Haruna, Y., K. Saito, S. Spaulding, M. A. Nalesnik, and M. A. Gerber. 1996. Identification of bipotential progenitor cells in human liver development. Hepatology 23:476-481.
15. Jung, Y., J. S. Isaacs, S. Lee, J. Trepel, Z. G. Liu, and L. Neckers. 2003. Hypoxia-inducible factor induction by tumour necrosis factor in normoxic cells requires receptor-interacting protein-dependent nuclear factor κB activation. Biochem. J. 370:1011-1017.
16. Jung, Y. J., J. S. Isaacs, S. Lee, J. Trepel, and L. Neckers. 2003. Microtubule disruption utilizes an NF-κB-dependent pathway to stabilize HIF-1α protein. J. Biol. Chem. 278:7445-7452.
17. Kallio, P. J., S. O'Brien, Y. Makino, and L. Poellinger, L. 1999. Regulation of the hypoxia-inducible transcription factor 1α by the ubiquitin-proteasome pathway. J. Biol. Chem. 274:6519.
18. Kallio, P. J., W. W. O'Brien, S. Makino, and L. Poellinger. 1998. Signal transduction in hypoxic cells: inducible nuclear translocation and recruitment of the CBP/p300 coactivator by the hypoxia. EMBO J. 17:6573.
19. Kami, R., Y. Dor, E. Keshet, O. Meyuhas, and A. Levitzki. 2002. Activated pp60c-Src leads to elevated hypoxia-inducible factor (HIF)-1α expression under normoxia. J. Biol. Chem. 277:42919-42925.
20. Leung, D. W., G. Cachianes, W. J. Kuang, D. V. Goeddel, and N. Ferrara. 1989. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306-1309.
21. Levrero, M. 2006. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 25:3834-3847.
22. Liu, X. H., A. Kirschenbaum, M. Lu, S. Yao, A. Dosoretz, J. F. Holland, and A. C. Levine. 2002. Prostaglandin E2 induces hypoxia-inducible factor-1α stabilization and nuclear localization in a human prostate cancer cell line. J. Biol. Chem. 277:50081-50086.
23. Machida, K., K. T. Cheng, V. M. Sung, S. Shimodaira, K. L. Lindsay, A. M. Levine, M. Y. Lai, and M. M. Lai. 2004. Hepatitis C virus induces a mutator phenotype: enhanced mutations of immunoglobulin and proto-oncogenes. Proc. Natl. Acad. Sci. USA 101:4262-4267.
24. Maxwell, P. H., G. U. Dachs, J. M. Gleadle, L. G. Nicholls, A. L. Harris, I. J. Stratford, O. Hankinson, C. W. Pugh, and P. J. Ratcliffe. 1997. Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth. Proc. Natl. Acad. Sci. USA 94:8104-8109.
25. Moradpour, D., R. Gosert, D. Egger, F. Penin, H. E. Blum, and K. Bienz. 2003. Membrane association of hepatitis C virus nonstructural proteins and identification of the membrane alteration that harbors the viral replication complex. Antivir. Res. 60:103-109.
26. Nunez, O., A. Fernandez-Martinez, P. L. Majano, A. Apolinario, M. Gomez-Gonzalo, I. Benedicto, M. Lopez-Cabrera, L. Bosca, G. Clemente, C. Garcia-Monzon, and P. Martin-Sanz. 2004. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. Gut 53:1665-1672.
27. Penin, F. 2003. Structural biology of hepatitis C virus. Clin. Liver Dis. 7:1-21.
28. Polyak, S. J., K. S. Khabar, D. M. Paschal, H. J. Ezelle, G. Duverlie, G. N. Barber, D. E. Levy, N. Mukaida, and D. R. Gretch. 2001. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J. Virol. 75:6095-6106.
29. Polyak, S. J., K. S. Khabar, M. Rezeiq, and D. R. Gretch. 2001. Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J. Virol. 75:6209-6211.
30. Poulsen, H. E., H. Prieme, and S. Loft. 1998. Role of oxidative DNA damage in cancer initiation and promotion. Eur. J. Cancer Prev. 7:9-16.
31. Ramanathan, M., G. Pinhal-Enfield, I. Hao, and S. J. Leibovich. 2007. Synergistic upregulation of vascular endothelial growth factor (VEGF) expression in macrophages by adenosine A2A receptor agonists and endotoxin involves transcriptional regulation via the hypoxia response element in the VEGF promoter. Mol. Biol. Cell 18:14-23.
32. Richard, D. E., E. Berra, and J. Pouyssegur. 1999. Angiogenesis: how a tumor adapts to hypoxia. Biochem. Biophys. Res. Commun. 266:718-722.
33. Roos, E., and K. P. Dingemans. 1979. Mechanisms of metastasis. Biochim. Biophys. Acta 560:135-166.
34. Schwartz, K. B. 1996. Oxidative stress during viral infection: a review. Free Radic. Biol. Med. 21:641-649.
35. Semela, D., and J. F. Dufour. 2004. Angiogenesis and hepatocellular carcinoma. J. Hepatol. 41:864-880.
36. Semenza, G. L. 2003. Angiogenesis in ischemic and neoplastic disorders. Annu. Rev. Med. 54:17-28.
37. Semenza, G. L. 2003. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 3:721-732.
38. Sumpter, R., Jr., C. Wang, E. Foy, Y. M. Loo, and M. Gale, Jr. 2004. Viral evolution and interferon resistance of hepatitis C virus RNA replication in a cell culture model. J. Virol. 78:11591-11604.
39. Tardif, K. D., G. Waris, and A. Siddiqui. 2005. Hepatitis C virus, ER stress, and oxidative stress. Trends Microbiol. 13:159-163.
40. Wakita, T., T. Pietschmann, T. Kato, T. Date, M. Miyamoto, Z. Zhao, K. Murthy, A. Habermann, H. G. Krausslich, M. Mizokami, R. Bartenschlager, and T. J. Liang. 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 11:791-796.
41. Waris, G., and A. Siddiqui. 2005. Hepatitis C virus stimulates the expression of cyclooxygenase-2 via oxidative stress: role of prostaglandin E2 in RNA replication. J. Virol. 79:9725-9734.
42. Waris, G., K. D. Tardif, and A. Siddiqui. 2002. Endoplasmic reticulum (ER) stress: hepatitis C virus induces an ER-nucleus signal transduction pathway and activates NF-κB and STAT-3. Biochem. Pharmacol. 64:1425-1430.
43. Waris, G., J. Turkson, T. Hassanein, and A. Siddiqui. 2005. Hepatitis C virus (HCV) constitutively activates STAT-3 via oxidative stress: role of STAT-3 in HCV replication. J. Virol. 79:1569-1580.
44. Xu, Q., J. Briggs, S. Park, G. Niu, M. Kortylewski, S. Zhang, T. Gritsko, J. Turkson, H. Kay, G. L. Semenza, J. Q. Cheng, R. Jove, and H. Yu. 2005. Targeting Stat3 blocks both HIF-1 and VEGF expression induced by multiple oncogenic growth signaling pathways. Oncogene 24:5552-5560.
45. Yahata, Y., Y. Shirakata, S. Tokumaru, K. Yamasaki, K. Sayama, Y. Hanakawa, M. Detmar, and K. Hashimoto. 2003. Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation. J. Biol. Chem. 278:40026-40031.
46. Yoo, Y. G., S. H. Oh, E. S. Park, H. Cho, N. Lee, H. Park, D. K. Kim, D. Y. Yu, J. K. Seong, and M. O. Lee. 2003. Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-lalpha through activation of mitogen-activated protein kinase pathway. J. Biol. Chem. 278:39076-39084.
47. Zhong, H., K. Chiles, D. Feldser, E. Laughner, C. Hanrahan, M. M. Georgescu, J. W. Simons, and G. L. Semenza. 2000. Modulation of hypoxia-inducible factor 1α expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. Cancer Res. 60:1541-1545.
48. Zhong, H., A. M. De Marzo, E. Laughner, M. Lim, D. A. Hilton, D. Zagzag, P. Buechler, W. B. Isaacs, G. L. Semenza, and J. W. Simons. 1999. Overexpression of hypoxia-inducible factor 1α in common human cancers and their metastases. Cancer Res. 59:5830-5835.
49. Zhong, J., P. Gastaminza, G. Cheng, S. Kapadia, T. Kato, D. R. Burton, S. F. Wieland, S. L. Uprichard, T. Wakita, and F. V. Chisari. 2005. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. USA 102:9294-9299.
50. Zundel, W., C. Schindler, D. Haas-Kogan, A. Koong, F. Kaper, E. Chen, A. R. Gottschalk, H. E. Ryan, R. S. Johnson, A. B. Jefferson, D. Stokoe, and A. J. Giaccia. 2000. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev. 14:391-396.